Oral phosphate binders

Kidney International

Volumn 75, Issue 9, 2009, Pages 906-914

  Hutchison, Alastair J ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Calcium; Hyperphosphatemia; Lanthanum carbonate; Phosphate binders; Renal dialysis; Sevelamer

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; CALCIUM ACETATE; CALCIUM ALGINATE; CALCIUM CARBONATE; CALCIUM KETOGLUTARATE; CALCIUM LACTATE; CALCIUM SALT; CERIUM OXIDE; GADOLINIUM; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CARBONATE; MAGNESIUM IRON HYDROXYCARBONATE; MAGNESIUM SALT; NICOTINAMIDE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG;

ADYNAMIC BONE DISEASE; ALUMINUM OVERLOAD; ANEMIA; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIFICATION; CLINICAL TRIAL; COGNITIVE DEFECT; DIALYSIS; DIET RESTRICTION; DRUG ABSORPTION; DRUG BINDING; DRUG COST; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LIVER TOXICITY; METABOLIC ACIDOSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; OSTEOMALACIA; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; SURVIVAL RATE; TREATMENT OUTCOME;

CHELATING AGENTS; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; PHOSPHATES; POLYAMINES; RENAL DIALYSIS;

EID: 64949135289     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.60     Document Type: Article

References (103)

1. Burke SK Phosphate is a uremic toxin J Ren Nutr 2008; 18 27-32.
2. Foley RN, Parfrey PS, Harnett JD et al Hypocalcemia, morbidity, and mortality in end-stage renal disease Am J Nephrol 1996; 16 386-393.
3. Lamb EJ, Hodsman A, van SD et al. Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (chapter 9). Nephrol Dial Transplant 2007; 22(Suppl 7): vii105-vii118.
4. Strippoli GF, Craig JC, Schena FP The number, quality, and coverage of randomized controlled trials in nephrology J Am Soc Nephrol 2004; 15 411-419.
5. Lowrie EG, Lew NL Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 1990; 15 458-482.
6. Delmez JA, Slatopolsky E Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease Am J Kidney Dis 1992; 19 303-317.
7. Block GA, Klassen PS, Lazarus JM et al Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 2004; 15 2208-2218.
8. Bushinsky DA. Phosphate binders: hold the calcium? Clin J Am Soc Nephrol 2006; 1: 695-696.
9. Mathew S, Tustison KS, Sugatani T et al The mechanism of phosphorus as a cardiovascular risk factor in CKD J Am Soc Nephrol 2008; 19 1092-1105.
10. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003; 16: 186-188.
11. Uribarri J Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake Semin Dial 2007; 20 295-301.
12. Kopple JD, Coburn JW. Metabolic studies of low protein diets in uremia. II Calcium, phosphorus and magnesium Medicine (Baltimore) 1973; 52 597-607.
13. Delmez JA, Slatopolsky E, Martin KJ et al Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis Kidney Int 1982; 21 862-867.
14. Wills MR, Savory J Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia Lancet 1983; 2 29-34.
15. Gonzalez-Revalderia J, Casares M, de PM et al Biochemical and hematological changes in low-level aluminum intoxication Clin Chem Lab Med 2000; 38 221-225.
16. Becaria A, Campbell A, Bondy SC Aluminum as a toxicant Toxicol Ind Health 2002; 18 309-320.
17. Ruster M, Abendroth K, Lehmann G et al Aluminum deposition in the bone of patients with chronic renal failure - detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine Clin Nephrol 2002; 58 305-312.
18. Jaffe JA, Liftman C, Glickman JD Frequency of elevated serum aluminum levels in adult dialysis patients Am J Kidney Dis 2005; 46 316-319.
19. Andrade LG, Garcia FD, Silva VS et al Dialysis encephalopathy secondary to aluminum toxicity, diagnosed by bone biopsy Nephrol Dial Transplant 2005; 20 2581-2582.
20. Nakagawa S, Ogura M, Akiba T et al. Development of nonaluminum phosphate binder hydrous cerium oxide (Ce alpha (OH)4-2 alphanH2O) Trans Am Soc Artif Intern Organs 1985; 31 155-159.
21. Slatopolsky E, Weerts C, Stokes T et al Alternative phosphate binders in dialysis patients: calcium carbonate Semin Nephrol 1986; 6 35-41.
22. Schaefer K, Umlauf E, von HD Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night Am J Kidney Dis 1992; 19 460-464.
23. Hutchison AJ, Whitehouse RW, Freemont AJ et al Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients Am J Nephrol 1994; 14 19-29.
24. Goodman WG, London G, Amann K et al Vascular calcification in chronic kidney disease Am J Kidney Dis 2004; 43 572-579.
25. Mallick NP, Berlyne GM Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure Lancet 1968; 2 1316-1320.
26. Almirall J, Veciana L, Llibre J Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients Am J Nephrol 1994; 14 192-196.
27. Caravaca F, Santos I, Cubero JJ et al Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients Nephron 1992; 60 423-427.
28. Pflanz S, Henderson IS, McElduff N et al Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis Nephrol Dial Transplant 1994; 9 1121-1124.
29. Ring T, Nielsen C, Andersen SP et al Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study Nephrol Dial Transplant 1993; 8 341-346.
30. Qunibi WY, Hootkins RE, McDowell LL et al Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study) Kidney Int 2004; 65 1914-1926.
31. Harris DC, Yuill L Calcium alginate versus aluminum hydroxide in patients on hemodialysis Nephron 1993; 65 324-325.
32. Passlick J, Wilhelm M, Busch T et al Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD Clin Nephrol 1989; 32 96-100.
33. Takahashi N, Shoji T, Matsubara K et al Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients J Am Soc Nephrol 1999; 10 1090-1094.
34. Birck R, Zimmermann E, Wassmer S et al Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study Nephrol Dial Transplant 1999; 14 1475-1479.
35. Macia M, Coronel F. Serum phosphate control: what about calcium salts of keto-amino acids? Nephrol Dial Transplant 1995; 10: 2159-2160.
36. Schaefer K, von HD, Asmus G et al The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia Clin Nephrol 1988; 30 93-96.
37. Hutchison AJ, Boulton H, Freemont A et al. Effective control of phosphate, intact PTH and osteodystrophy by low calcium dialysis fluid and oral CaCO3 in CAPD. Perit Dial Int 1992; 12(Suppl 2): S35.
38. Hunt CD, Johnson LK Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies Am J Clin Nutr 2007; 86 1054-1063.
39. Hutchison AJ, Boulton HF, Herman K et al Use of oral stable strontium to provide an index of intestinal calcium absorption in chronic ambulatory peritoneal dialysis patients Miner Electrolyte Metab 1992; 18 160-165.
40. Sigrist M, McIntyre CW Calcium exposure and removal in chronic hemodialysis patients J Ren Nutr 2006; 16 41-46.
41. Friedman EA Calcium-based phosphate binders are appropriate in chronic renal failure Clin J Am Soc Nephrol 2006; 1 704-709.
42. Moe SM, Chertow GM The case against calcium-based phosphate binders Clin J Am Soc Nephrol 2006; 1 697-703.
43. Friedman EA Calcium-based phosphate binders are appropriate in chronic renal failure Clin J Am Soc Nephrol 2006; 1 704-709.
44. Suki WN, Zabaneh R, Cangiano JL et al Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients Kidney Int 2007; 72 1130-1137.
45. Spiegel DM, Farmer B, Smits G et al Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study J Ren Nutr 2007; 17 416-422.
46. Delmez JA, Kelber J, Norword KY et al Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study Kidney Int 1996; 49 163-167.
47. O'Donovan R, Baldwin D, Hammer M et al Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia Lancet 1986; 1 880-882.
48. Nilsson P, Johansson SG, Danielson BG Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium Nephron 1984; 37 25-29.
49. Hutchison AJ, Were AJ, Boulton HF et al Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations Nephron 1996; 72 52-58.
50. Hutchison AJ, Merchant M, Boulton HF et al. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/l calcium, 025 mmol/l magnesium dialysis fluid Perit Dial Int 1993; 13 219-223.
51. Meema HE, Oreopoulos DG, Rapoport A Serum magnesium level and arterial calcification in end-stage renal disease Kidney Int 1987; 32 388-394.
52. Velentzas C, Meindok H, Oreopoulos DG et al Visceral calcification and the CaXP product Adv Exp Med Biol 1978; 103 195-201.
53. Ishimura E, Okuno S, Kitatani K et al Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients Clin Nephrol 2007; 68 222-227.
54. Turgut F, Kanbay M, Metin MR et al Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis Int Urol Nephrol 2008; 40 1075-1082.
55. Graff L, Burnel D Reduction of dietary phosphorus absorption by oral phoshorus binders Res Commun Mol Pathol Pharmacol 1995; 90 389-401.
56. Graff L, Burnel D A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphorus absorption Res Commun Mol Pathol Pharmacol 1995; 89 373-388.
57. Wilkes BM, Reiner D, Kern M et al Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients Clin Nephrol 1998; 50 381-386.
58. Bleyer AJ, Burke SK, Dillon M et al A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients Am J Kidney Dis 1999; 33 694-701.
59. Chertow GM, Burke SK, Raggi P Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 2002; 62 245-252.
60. Brewster UC, Ciampi MA, bu-Alfa AK et al Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders Nephrology (Carlton) 2006; 11 142-146.
61. Suki WN Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial J Ren Nutr 2008; 18 91-98.
62. St Peter WL, Liu J, Weinhandl E et al A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data Am J Kidney Dis 2008; 51 445-454.
63. Asmus HG, Braun J, Krause R et al Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density Nephrol Dial Transplant 2005; 20 1653-1661.
64. Hutchison AJ, Maes B, Vanwalleghem J et al Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study Nephron Clin Pract 2006; 102 c61-c71.
65. Finn WF Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients Clin Nephrol 2006; 65 191-202.
66. Hutchison AJ, Maes B, Vanwalleghem J et al Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate Nephron Clin Pract 2005; 100 c8-c19.
67. Block GA, Raggi P, Bellasi A et al Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients Kidney Int 2007; 71 438-441.
68. Block GA, Spiegel DM, Ehrlich J et al Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis Kidney Int 2005; 68 1815-1824.
69. Delmez J, Block G, Robertson J et al A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis Clin Nephrol 2007; 68 386-391.
70. Damment SJ, Pennick M Systemic lanthanum is excreted in the bile of rats Toxicol Lett 2007; 171 69-77.
71. Pennick M, Dennis K, Damment SJ Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate J Clin Pharmacol 2006; 46 738-746.
72. Bervoets AR, Behets GJ, Schryvers D et al Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure Kidney Int 2009; 75 389-398.
73. Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden Nephrol Dial Transplant 2008; 23 3677-3684.
74. Drueke TB Lanthanum carbonate as a first-line phosphate binder: the 'cons' Semin Dial 2007; 20 329-332.
75. D'Haese PC, Spasovski GB, Sikole A et al A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients Kidney Int Suppl 2003; 85 S73-S78.
76. Hutchison AJ, Barnett ME, Krause R et al Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment Nephron Clin Pract 2008; 110 c15-c23.
77. Aime S, Canavese C, Stratta P Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate Kidney Int 2007; 72 1162-1163.
78. Smyth MD, Pratt RD Letter regarding 'Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate' Kidney Int 2008; 74 536; author reply 536-537.
79. De Broe ME. Can the risk of gadolinium be extrapolated to lanthanum? Semin Dial 2008; 21: 142-144.
80. McIntyre CW New developments in the management of hyperphosphatemia in chronic kidney disease Semin Dial 2007; 20 337-341.
81. Rude RK, Gruber HE, Norton HJ et al Dietary magnesium reduction to 25% of nutrient requirement disrupts bone and mineral metabolism in the rat Bone 2005; 37 211-219.
82. Rude RK, Gruber HE Magnesium deficiency and osteoporosis: animal and human observations J Nutr Biochem 2004; 15 710-716.
83. Wallach S Relation of magnesium to osteoporosis and calcium urolithiasis Magnes Trace Elem 1991; 10 281-286.
84. Wallach S Effects of magnesium on skeletal metabolism Magnes Trace Elem 1990; 9 1-14.
85. Navarro JF, Macia ML, Gallego E et al Serum magnesium concentration and PTH levels Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease? Scand J Urol Nephrol 1997; 31 275-280.
86. Jung GJ, Gil HW, Yang JO et al Severe hypermagnesemia causing quadriparesis in a CAPD patient Perit Dial Int 2008; 28 206.
87. Schelling JR Fatal hypermagnesemia Clin Nephrol 2000; 53 61-65.
88. Katai K, Tanaka H, Tatsumi S et al Nicotinamide inhibits sodiumdependent phosphate cotransport activity in rat small intestine Nephrol Dial Transplant 1999; 14 1195-1201.
89. Takahashi Y, Tanaka A, Nakamura T et al Nicotinamide suppresses hyperphosphatemia in hemodialysis patients Kidney Int 2004; 65 1099-1104.
90. Eto N, Miyata Y, Ohno H et al Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure Nephrol Dial Transplant 2005; 20 1378-1384.
91. Kirchner S, Muduli A, Casirola D et al Luminal fructose inhibits rat intestinal sodium-phosphate cotransporter gene expression and phosphate uptake Am J Clin Nutr 2008; 87 1028-1038.
92. Ford JC, Pope JF, Hunt AE et al The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia J Ren Nutr 2004; 14 36-44.
93. Kuhlmann MK, Hoechst S, Landthaler I Patient empowerment in the management of hyperphosphatemia Int J Artif Organs 2007; 30 1008-1013.
94. Kuhlmann MK Management of hyperphosphatemia Hemodial Int 2006; 10 338-345.
95. Sun CY, Chang KC, Chen SH et al Patient education: an efficient adjuvant therapy for hyperphosphatemia in hemodialysis patients Ren Fail 2008; 30 57-62.
96. Chandrasekharan L, Ramlan G, Harnett P et al PHOS GRAPH a novel tool in hyperphosphataemia management in haemodialysis patients J Hum Nutr Diet 2008; 21 384-385.
97. Twain M. Chapters from my autobiography XX. North American Review 1907; DCXVIII: 465-474.
98. Eknoyan G, Levin A, Levin N K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 2003; 42 S10-S201.
99. What Are the Key Statistics About Ovarian Cancer? American Cancer Society. 19-1-2008. American Cancer Society. 11-9-2008. Ref Type: Electronic Citation.
100. Coyne DW Practice recommendations based on low, very low, and missing evidence Clin J Am Soc Nephrol 2007; 2 11-12.
101. Al AZ, Gonzalez EA, Martin KJ et al Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle Am J Nephrol 2004; 24 422-426.
102. Manns B, Owen Jr WF, Winkelmayer WC et al. Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis 2006; 48: 159-166.
103. Winkelmayer WC, Tonelli M Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice Am J Kidney Dis 2008; 51 362-365.